After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future ...

Hims & Hers delivered yet another strong quarter of revenue growth in Q3, with sales climbing 49% year over year to $599 ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new ...

This week, the parents of Luke Tyler, the Washington State University (WSU) freshman who was found dead in his dorm room on January 22, 2023, filed a wrongful death lawsuit in the King County Superior ...

Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...

Hims & Hers Health (HIMS) stock is in focus as the firm launches Labs, a product offering preventive care through insights ...

Hims & Hers launches Labs, offering annual biomarker testing plans with doctor-developed guidance and expanded diagnostics planned across key health categories.

The parents of Luke Tyler, a WSU freshman found dead in his dorm, allege his death was a consequence of Hims' reckless ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Hims & Hers Health recently reported third-quarter results with revenues of US$598.98 million, net income of US$15.77 million, and impairment charges of US$531,000, while also narrowing full-year 2025 ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...